Christopher K. Bichakjian

Christopher K. Bichakjian

Auto-generated profile, based on publicly available information

Christopher K. Bichakjian

Department of Dermatology, Michigan Medicine/University of Michigan, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2019 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
NKNour Kibbi
Nour Kibbi
BWBrandon Worley
Brandon Worley
JOJoshua L. Owen
Joshua L. Owen
RKRyan C. Kelm
Ryan C. Kelm
CBChristopher K. Bichakjian
Christopher K. Bichakjian
MAMurad Alam
Murad Alam

1 August 2006 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
SMStanley J Miller
Stanley J Miller
MAMurad Alam
Murad Alam
JAJames Andersen
James Andersen
DBDaniel Berg
Daniel Berg
CBChristopher K Bichakjian
Christopher K Bichakjian
NNNational Comprehensive Cancer Network
National Comprehensive Cancer Network
Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer with the regional and distant metastatic rates of thick melanoma. The mortality rate of MCC exceeds that of melanoma, and the 5-year disease-specific survival rate is 64%. These guidelines and most biomedical literature suggest that the workup of a patient with MCC should include chest radiograph and additional studies as clinically indicated. These guidelines, which the NCCN Non-Melanoma Skin Cancer Panel developed as a supplement to those for squamous cell and basal cell skin cancer, also outline treatment strategies. For the most recent version of the guidelines, please visit NCCN.org

10 March 2014 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Open access
PDF file
JSJennifer L. Schwartz
Jennifer L. Schwartz
SWSandra L. Wong
Sandra L. Wong
SMScott A. McLean
Scott A. McLean
JHJames A. Hayman
James A. Hayman
CLChristopher D. Lao
Christopher D. Lao
CBChristopher K. Bichakjian
Christopher K. Bichakjian
Merkel cell carcinoma (MCC) is a rare malignancy of the skin, and prospective randomized clinical studies on management and treatment are very limited. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MCC provide up-to-date, best evidence-based, and consensus-driven management pathways with the purpose of providing best care and outcomes. Multidisciplinary management with consensus treatment recommendations to individualize patient care within the framework of these guidelines is optimal. The University of Michigan multidisciplinary MCC program uses NCCN Guidelines in the management and treatment of its patients. This article discusses 4 patient presentations to highlight the implementation of the NCCN Guidelines for MCC at the University of Michigan. Merkel cell carcinoma (MCC) is a rare malignancy of the skin, and prospective randomized clinical studies on management and treatment are very limited. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MCC provide up-to-date, best evidence-based, and consensus-driven management pathways with the purpose of providing best care and outcomes. Multidisciplinary management with consensus treatment recommendations to individualize patient care within the framework of these guidelines is optimal. The University of Michigan multidisciplinary MCC program uses NCCN Guidelines in the management and treatment of its patients. This article discusses 4 patient presentations to highlight the implementation of the NCCN Guidelines for MCC at the University of Michigan.

1 September 2011 in Dermatologic Surgery
Verified
Journal Article
Open access
MLMathew W. Ludgate
Mathew W. Ludgate
MSMichael S. Sabel
Michael S. Sabel
DFDouglas R. Fullen
Douglas R. Fullen
MFMarcus L. Frohm
Marcus L. Frohm
JLJulia S. Lee
Julia S. Lee
CBChristopher K. Bichakjian
Christopher K. Bichakjian
To evaluate perceived anxiety levels and overall satisfaction after searching the Internet of people with skin cancer. METHODS & MATERIALS We conducted a survey study and prospectively collected data from people newly diagnosed with melanoma or NMSC. RESULTS Four hundred fifteen participants with melanoma and 400 with NMSC completed the questionnaire. Internet use and overall satisfaction with the Internet search increased more than 50% in participants with melanoma from 2005. One-third of participants with melanoma, but many fewer participants with NMSC, reported higher anxiety after Internet use. Participants who were younger, female, more highly educated, and diagnosed with melanoma were most likely to use the Internet to search for information about their diagnosis. CONCLUSION Internet use is prevalent and increasing sharply in individuals with skin cancer. The majority of individuals describe their use of the Internet as a positive experience. Greater anxiety from searching the Internet is more common in individuals with melanoma than in those with NMSC. The authors have indicated no significant interest with commercial supporters....

8 April 2016 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Open access
PDF file
AJAndrew L. Ji
Andrew L. Ji
CBChristopher K. Bichakjian
Christopher K. Bichakjian
SSSusan M. Swetter
Susan M. Swetter
Molecular profiling of malignant tumors is gaining increasing interest in oncology. In recent years, several molecular techniques have been studied in melanoma, with the goal to improve upon the diagnostic and prognostic abilities of currently available clinical and histopathologic parameters. Reliable tests performed early in the diagnosis and management of melanoma could lead to decreased morbidity and mortality by selecting appropriate patients for more-aggressive therapy and sparing those for whom it is not indicated. This article reviews the molecular diagnostic and prognostic techniques currently available for melanoma and evaluates their potential role in clinical practice. Molecular profiling of malignant tumors is gaining increasing interest in oncology. In recent years, several molecular techniques have been studied in melanoma, with the goal to improve upon the diagnostic and prognostic abilities of currently available clinical and histopathologic parameters. Reliable tests performed early in the diagnosis and management of melanoma could lead to decreased morbidity and mortality by selecting appropriate patients for more-aggressive therapy and sparing those for whom it is not indicated. This article reviews the molecular diagnostic and prognostic techniques currently available for melanoma and evaluates their potential role in clinical practice.

21 July 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
JSJoshua D. Smith
Joshua D. Smith
ABApurva D. Bhangale
Apurva D. Bhangale
WGWenjin Gu
Wenjin Gu
CBCollin Brummel
Collin Brummel
EGElizabeth Gensterblum-Miller
Elizabeth Gensterblum-Miller
JBJ. Chad Brenner
J. Chad Brenner
Merkel cell carcinoma (MCC) is an aggressive disease with poor survival outcomes and increasing incidence. There is a clear and present need for enhanced understanding of cellular mechanisms of tumorigenesis, validation of robust genetic signatures predictive of aggressive disease, and novel informatics tools to simplify analysis of Merkel cell polyomavirus (MCPyV)–host genome interactions. Genomic DNA was harvested from 54 MCC tumors for exome sequencing and in-depth genetic profiling of a 226-gene panel. We further developed a robust informatics package (MCPyViewer) optimized for MCPyV integration site analysis with graphical output to simplify usability for end users. Finally, we assessed the prognostic impact of specific genetic signatures on MCC-specific survival in our cohort. Our study included 54 patients (n = 44 MCPyV positive), 11 (20.4%) of whom had died of MCC at last follow-up. Human genes altered at high frequency included LRP1B (n = 10, 18.5%), FAT1 (n = 9, 16.7%), KMT2D (n = 9, 16.7%), and RB1 (n = 7, 13.0%). In 36 of 44 (81.8%) MCPyV-positive tumors, we identified viral integration into the human genome with a median of two events per tumor. In six tumors, MCPyV integrated into Catalogue of Somatic Mutations in Cancer tier 1 or tier 2 cancer-related human genes. Implications: A combined genomics score incorporating tumor mutational burden and copy-number variation was strongly prognostic of MCC-specific survival controlling for lymph node metastases and tumor MCPyV status; thus, our study adds critical understanding to prognostic markers and tumorigenic mechanisms in MCC.